Lung cancer screening with volume computed tomography is cost-effective in Greece
LCS with volume-based LDCT, targeting an asymptomatic high-risk population, is highly cost-effective in Greece. Implementing LCS ensures efficient allocation of public healthcare resources while delivering substantial clinical benefits to lung cancer patients.
Authors
- Georgia Kourlaba (ORCID: https://orcid.org/0000-0002-1364-9488)
- Kyriaki Tavernaraki
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Sofia Agelaki (ORCID: https://orcid.org/0000-0002-7850-0457)
- Εleftherios Ζervas (ORCID: https://orcid.org/0000-0001-7436-4550)
- Sofia Lampaki
- Lisa A. de Jong (ORCID: https://orcid.org/0000-0001-8814-0670)
- Konstantinos N. Syrigos (ORCID: https://orcid.org/0000-0002-3474-1363)
- Hilde ten Berge
- Harry J.M. Groen (ORCID: https://orcid.org/0000-0002-2978-5265)
- Christophoros N. Foroulis (ORCID: https://orcid.org/0000-0002-5708-7210)
- Xuanqi Pan (ORCID: https://orcid.org/0000-0001-5237-3544)
- Ioannis Gkiozos (ORCID: https://orcid.org/0000-0002-2902-3391)
- K. Togka
- Antonios Moraris
Institutions
- University Medical Center Groningen (NL)
- University of Peloponnese (GR)
- University of Groningen (NL)
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- AHEPA University Hospital (GR)
- University Hospital of Heraklion (GR)
- G. Papanikolaou General Hospital (GR)
- Sotiria General Hospital (GR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1371/journal.pone.0316351
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- AstraZeneca